• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CME Group Inc.

    3/13/26 2:16:05 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance
    Get the next $CME alert in real time by email
    S-8 1 d120078ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 13, 2026.

    Registration No. 333-   

    United States Securities and Exchange Commission

    Washington, DC 20549

    Form S-8

    Registration Statement Under the Securities Act of 1933

    CME Group Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   36-4459170

    (State or other jurisdiction of incorporation or

    organization)

      (I.R.S. Employer Identification No.)

    20 South Wacker Drive

    Chicago, Illinois

      60606
    (Address of Principal Executive Offices)   (Zip Code)

    CME Group Inc. Fourth Amended and Restated Omnibus Stock Plan

    (Full title of the plan)

    Jonathan Marcus, Esq.

    Senior Managing Director and General Counsel

    CME Group Inc.

    20 South Wacker Drive

    Chicago, Illinois 60606

    (Name and address of agent for service)

    (312) 930-1000

    (Telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☒      Accelerated filer ☐                    
    Non-accelerated filer ☐      Smaller reporting company ☐    
         Emerging growth company ☐    

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


    EXPLANATORY NOTE

    CME Group Inc. (the “Company”) is filing this registration statement for the purpose of registering 1,500,000 shares of the Company’s Class A Common Stock, par value $.01 per share (the “Class A Common Stock”), authorized for issuance in connection with awards under the CME Group Inc. Fourth Amended and Restated Omnibus Stock Plan (the “Omnibus Stock Plan”).

    Part I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The documents containing the information specified in Part I of Form S-8 will be sent or given to participants in the Omnibus Stock Plan as required by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with Rule 428(b) under the Securities Act and the note to Part I of Form S-8, those documents are not being filed with the Securities and Exchange Commission (the “SEC”) as a part of this registration statement.

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed with the SEC by the Company pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference in this registration statement:

     

      •  

    the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026; and

     

      •  

    the description of the Class  A Common Stock set forth in Exhibit 4.11 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 2, 2022.

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Item 4. Description of Securities.

    Not applicable.

     

    2


    Item 5. Interests of Named Experts and Counsel.

    The validity of the shares of Class A Common Stock being registered pursuant to this registration statement has been passed upon by Margaret A. Wright, Associate General Counsel of the Company. Ms. Wright is a beneficial owner of shares of Class A Common Stock and is eligible to participate in the CME Group Inc. Fourth Amended and Restated Omnibus Stock Plan.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”) authorizes a court to award or a corporation’s board of directors to grant indemnity to directors and officers in terms sufficiently broad to permit such indemnification under some circumstances for liabilities arising under the Securities Act and to provide for the reimbursement of expenses incurred.

    As permitted by Delaware law, Article Eleven of the Company’s certificate of incorporation and Article VIII of the Company’s bylaws provide that (1) the Company shall indemnify its directors and officers and former directors and officers to the fullest extent permitted by law; (2) such indemnification includes the right to advancement of expenses if the Company has received an undertaking by the person receiving such advance to repay all amounts advanced if it should be determined that he or she is not entitled to be indemnified by the Company; and (3) the rights to indemnification conferred in the Company’s certificate of incorporation and bylaws are not exclusive. As permitted by the DGCL, Article Ten of the Company’s certificate of incorporation includes a provision that eliminates the personal liability of the Company’s directors for monetary damages for breach of fiduciary duty as a director, except for liability (a) for any breach of the director’s duty of loyalty to the Company or its shareholders; (b) for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; (c) under Section 174 of the DGCL (regarding payments of dividends, stock purchases or redemptions which are unlawful); or (d) for any transaction from which the director derived an improper personal benefit. This provision in the Company’s certificate of incorporation does not eliminate the directors’ fiduciary duty, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware law. In addition, each director will continue to be subject to liability for breach of the director’s duty of loyalty to the Company for acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for actions leading to improper personal benefit to the director and for payment of dividends or approval of stock repurchases or redemptions that are unlawful under Delaware law. The provision also does not affect a director’s responsibilities under any other law, such as the federal securities laws or state or federal environmental laws.

    The foregoing statements are subject to the detailed provisions of Section 145 of the DGCL and the full text of the Company’s certificate of incorporation and bylaws. Copies of the Company’s certificate of incorporation and bylaws have been filed as exhibits to this registration statement.

    The Company maintains, at its expense, a policy of insurance which insures its directors and officers, subject to exclusions and deductions as are usual in these kinds of insurance policies, against specified liabilities which may be incurred in those capacities.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

     

    3


    Item 8. Exhibits.

     

    Exhibit No.   

    Description

    4.1    Fourth Amended and Restated Certificate of Incorporation of CME Group Inc. (incorporated by reference to Exhibit  3.2 to CME Group Inc.’s Current Report on Form 8-K filed with the SEC on November 4, 2021).
    4.2    Seventeenth Amended and Restated Bylaws of CME Group Inc. (incorporated by reference to Exhibit  3.1 to CME Group Inc.’s Current Report on Form 8-K filed with the SEC on December 9, 2022).
    5.1    Opinion of Margaret A. Wright, Associate General Counsel of CME Group Inc.
    23.1    Consent of Ernst & Young LLP.
    23.2    Consent of Margaret A. Wright (included in Exhibit 5.1).
    24.1    Power of attorney (included on signature pages to this registration statement).
    99.1    CME Group Inc. Fourth Amended and Restated Omnibus Stock Plan (incorporated by reference to Exhibit  10.1 to CME Group Inc.’s Current Report on Form 8-K filed with the SEC on March 7, 2024).
    107    Filing fee table.

    Item 9. Undertakings.

     

    (a)

    The undersigned registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i)

    To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

     

      (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement.

     

      (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    Provided, however, That: Paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    4


      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)

    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)

    Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

    5


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Chicago, State of Illinois, on March 13, 2026.

     

    CME GROUP INC.
    By:  

    /S/ LYNNE FITZPATRICK

      Lynne Fitzpatrick
      President and Chief Financial Officer

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints Terrence A. Duffy, Lynne Fitzpatrick and Jonathan Marcus, and each of them, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and any instruments necessary or appropriate in connection therewith, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing required or necessary to be done in and about the premises, as fully to all intents and purposes as such person may or could do in person, and hereby ratifies and confirms all that said attorneys-in-fact and agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney may be executed in counterparts.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities indicated on March 13, 2026.

     

    Signature

      

    Title

    /S/ TERRENCE A. DUFFY

    Terrence A. Duffy

       Chairman of the Board, Director and Chief Executive Officer (Principal Executive Officer and Director)

    /S/ LYNNE FITZPATRICK

    Lynne Fitzpatrick

       Senior Managing Director, President and Chief Financial Officer (Principal Financial Officer)

    /S/ JACK TOBIN

    Jack Tobin

       Managing Director and Chief Accounting Officer (Principal Accounting Officer)

    /S/ KATHRYN BENESH

    Kathryn Benesh

       Director


    Signature

      

    Title

    /S/ TIMOTHY S. BITSBERGER

    Timothy S. Bitsberger

       Director

    /S/ CHARLES P. CAREY

    Charles P. Carey

       Lead Director

    /S/ ELIZABETH A. COOK

    Elizabeth A. Cook

       Director

    /S/ BRYAN T. DURKIN

    Bryan T. Durkin

       Director

    /S/ HAROLD FORD JR.

    Harold Ford Jr.

       Director

    /S/ MARTIN J. GEPSMAN

    Martin J. Gepsman

       Director

    /S/ WILLIAM W. HOBERT

    William W. Hobert

       Director

    /S/ DANIEL G. KAYE

    Daniel G. Kaye

       Director

    /S/ PHYLLIS M. LOCKETT

    Phyllis M. Lockett

       Director

    /S/ DEBORAH J. LUCAS

    Deborah J. Lucas

       Director

    /S/ PATRICK W. MALONEY

    Patrick W. Maloney

       Director


    Signature

      

    Title

    /S/ PATRICK J. MULCHRONE

       Director
    Patrick J. Mulchrone   

    /S/ RAHAEL SEIFU

       Director
    Rahael Seifu   

    /S/ WILLIAM R. SHEPARD

       Director
    William R. Shepard   

    /S/ HOWARD J. SIEGEL

       Director
    Howard J. Siegel   

    /S/ DENNIS A. SUSKIND

       Director
    Dennis A. Suskind   

    /S/ ROBERT J. TIERNEY JR.

       Director
    Robert J. Tierney Jr.   
    Get the next $CME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CME

    DatePrice TargetRatingAnalyst
    3/4/2026Buy → Hold
    Argus
    1/14/2026$305.00Hold → Buy
    TD Cowen
    10/23/2025$300.00Hold → Buy
    Deutsche Bank
    9/25/2025$300.00Neutral → Buy
    Citigroup
    7/24/2025$305.00Buy → Neutral
    UBS
    4/8/2025$301.00Equal-Weight → Overweight
    Morgan Stanley
    3/10/2025$287.00Mkt Perform → Outperform
    Raymond James
    1/6/2025$255.00 → $250.00Buy → Neutral
    Citigroup
    More analyst ratings

    $CME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    MD Chief Accounting Officer Tobin Jack J gifted 105 units of Common Stock Class A, decreasing direct ownership by 0.42% to 24,980 units (SEC Form 4)

    4 - CME GROUP INC. (0001156375) (Issuer)

    3/12/26 5:48:01 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    Chief Transformation Officer Vroman Ken sold $1,594,440 worth of Common Stock Class A (5,160 units at $309.00), decreasing direct ownership by 26% to 14,910 units (SEC Form 4)

    4 - CME GROUP INC. (0001156375) (Issuer)

    3/12/26 5:46:24 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    Director Cook Elizabeth A sold $320,000 worth of Common Stock Class A (1,000 units at $320.00) (SEC Form 4)

    4 - CME GROUP INC. (0001156375) (Issuer)

    3/9/26 4:31:20 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    $CME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CME Group Inc. Announces First-Quarter 2026 Earnings Release, Conference Call

    CHICAGO, March 11, 2026 /PRNewswire/ -- CME Group Inc. will announce earnings for the first quarter of 2026 before the markets open on Wednesday, April 22, 2026. Written highlights for the quarter will be posted on the company's website at 6:00 a.m. Central Time, the same time it provides its earnings press release. The company will also hold an investor conference call that day at 7:30 a.m. Central Time, at which time company executives will take analysts' questions.  A live audio Webcast of the conference call will be available on the Investor Relations section of the company's website. Following the conference call, an archived recording will be available at the same site. Those wishing t

    3/11/26 3:00:00 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    CME Group Energy Complex Reaches All-Time Daily Volume Record of 8.3 Million Contracts

    CHICAGO, March 9, 2026 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that its energy complex reached a new single-day volume record of 8.3 million contracts on March 6, surpassing the previous daily record of 7.9 million contracts set on March 3, 2026. "As geopolitical shifts drive uncertainty throughout the global energy sector, market participants are turning to CME Group to manage their risk," said Peter Keavey, Global Head of Energy Products at CME Group. "In these volatile market conditions, clients continue to rely on our liquid markets and benchmark products to discover prices, hedge and adjust exposure within their portfolios."Other highlight

    3/9/26 8:41:00 AM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    CME Group Announces First Trades for South Asia Crude Palm Oil (Fastmarkets) Futures

    CHICAGO and SINGAPORE, March 9, 2025 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced a total of 100 contracts of the South Asia Crude Palm Oil (Fastmarkets) futures traded as a block between Avere Commodities and Olam Agri, brokered by ICAP, on March 5, 2026. CME Group launched its four new South Asia edible oil futures contracts, which are available for trading, on March 2, 2026. "We're pleased to see early industry support for our new South Asia edible oils futures contracts," said John Ricci, Managing Director and Global Head of Agricultural Products, CME Group. "The addition of these contracts provides South Asian market participants with enhanced

    3/8/26 10:00:00 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    $CME
    SEC Filings

    View All

    SEC Form S-8 filed by CME Group Inc.

    S-8 - CME GROUP INC. (0001156375) (Filer)

    3/13/26 2:16:05 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    SEC Form DEFA14A filed by CME Group Inc.

    DEFA14A - CME GROUP INC. (0001156375) (Filer)

    3/12/26 4:43:48 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    SEC Form PRE 14A filed by CME Group Inc.

    PRE 14A - CME GROUP INC. (0001156375) (Filer)

    3/12/26 4:10:09 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    $CME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shepard William R bought $73,008 worth of Common Stock Class A (262 units at $278.37), increasing direct ownership by 0.45% to 2,477 units (SEC Form 4)

    4 - CME GROUP INC. (0001156375) (Issuer)

    1/2/26 2:30:36 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    Director Shepard William R bought $72,672 worth of Common Stock Class A (274 units at $265.19), increasing direct ownership by 0.47% to 2,466 units (SEC Form 4)

    4 - CME GROUP INC. (0001156375) (Issuer)

    9/26/25 8:46:02 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    Director Shepard William R was granted 879 units of Common Stock Class A and bought $72,336 worth of Common Stock Class A (267 units at $270.53), increasing direct ownership by 0.46% to 2,455 units (SEC Form 4)

    4 - CME GROUP INC. (0001156375) (Issuer)

    6/26/25 6:11:41 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    $CME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CME Group downgraded by Argus

    Argus downgraded CME Group from Buy to Hold

    3/4/26 8:23:45 AM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    CME Group upgraded by TD Cowen with a new price target

    TD Cowen upgraded CME Group from Hold to Buy and set a new price target of $305.00

    1/14/26 8:20:33 AM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    CME Group upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded CME Group from Hold to Buy and set a new price target of $300.00

    10/23/25 9:04:53 AM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    $CME
    Financials

    Live finance-specific insights

    View All

    CME Group Inc. Announces First-Quarter 2026 Earnings Release, Conference Call

    CHICAGO, March 11, 2026 /PRNewswire/ -- CME Group Inc. will announce earnings for the first quarter of 2026 before the markets open on Wednesday, April 22, 2026. Written highlights for the quarter will be posted on the company's website at 6:00 a.m. Central Time, the same time it provides its earnings press release. The company will also hold an investor conference call that day at 7:30 a.m. Central Time, at which time company executives will take analysts' questions.  A live audio Webcast of the conference call will be available on the Investor Relations section of the company's website. Following the conference call, an archived recording will be available at the same site. Those wishing t

    3/11/26 3:00:00 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    CME Group Declares Annual Variable Dividend and Q1 2026 Quarterly Dividend

    CHICAGO, Feb. 12, 2026 /PRNewswire/ -- CME Group Inc., the world's leading derivatives marketplace, today declared its annual variable dividend and first-quarter regular dividend, both of which are payable March 26, 2026, to shareholders of record as of March 10, 2026: Annual variable dividend based on 2025 financial results of $6.15 per share totals approximately $2.2 billion.First-quarter regular dividend of $1.30 per share, a 5 cent increase from the prior level of $1.25 per share.Today's announced annual variable dividend based on 2025 financial results, when combined with quarterly dividends paid during 2025, will total approximately $4.0 billion, reflecting a total dividend yield of 4

    2/12/26 7:30:00 AM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    CME Group Inc. Reports Fourth Consecutive Year of Record Annual Revenue, Adjusted Operating Income, Adjusted Net Income and Adjusted Earnings Per Share for 2025

    Record annual revenue of $6.5 billion, up 6%Record annual market data revenue of $803 million, up 13%CHICAGO, Feb. 4, 2026 /PRNewswire/ -- CME Group Inc. (NASDAQ:CME) today reported financial results for the fourth quarter and full year of 2025. The company reported revenue of $1.6 billion and operating income of $1.0 billion for the fourth quarter of 2025. Net income was $1.2 billion and diluted earnings per common share were $3.24. On an adjusted basis, net income was $1.0 billion and diluted earnings per common share were $2.77. Financial results presented on an adjusted basis for the fourth quarter of 2025 and 2024 exclude certain items, which are detailed in the reconciliation of non-G

    2/4/26 7:00:00 AM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    $CME
    Leadership Updates

    Live Leadership Updates

    View All

    Leading Financial Institutions to Join BrokerTec Chicago for First Day of Trading

    New Central Limit Order Book for U.S. Treasury Trading to Launch Oct. 6CHICAGO, Sept. 4, 2025 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that Citigroup, J.P. Morgan and Morgan Stanley will be available to trade cash U.S. Treasuries on BrokerTec Chicago when it launches on October 6. "With leading financial firms on board for day one on BrokerTec Chicago, trading U.S. Treasury futures and cash will be more efficient than ever before," said Mike Dennis, CME Group Global Head of Fixed Income. "CME Group is in a unique position to bring these markets together, unlocking value for our clients worldwide who want to more precisely hedge their risk amid

    9/4/25 8:00:00 AM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    CME Group Inc. Announces Preliminary Results from its 2025 Annual Meeting of Shareholders

    CHICAGO, May 9, 2025 /PRNewswire/ -- CME Group Inc. (NASDAQ:CME) today announced the preliminary shareholder voting results from its 2025 annual meeting. At the meeting, shareholders: Elected Terrence A. Duffy, Kathryn Benesh, Timothy S. Bitsberger, Charles P. Carey, Bryan T. Durkin, Harold Ford Jr., Martin J. Gepsman, Daniel G. Kaye, Phyllis M. Lockett, Deborah J. Lucas, Rahael Seifu, William R. Shepard, Howard J. Siegel and Dennis A. Suskind, each for a one-year term expiring in 2026.Ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for 2025.Approved, on an advisory basis, the compensation of our named executive officers.There was

    5/9/25 10:29:00 AM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    CME Clearing Appoints New Chief Risk Officer

    CHICAGO, April 24, 2025 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced the appointment of Vijay Albuquerque as Chief Risk Officer (CRO) in its Clearing & Post-Trade Services Division.  With over 20 years' industry experience, Albuquerque most recently served as the Head of Counterparty Risk and Portfolio Risk Analytics for Citigroup's Markets and Banking businesses. Albuquerque will be based in New York and will report to Suzanne Sprague, CME Group Chief Operating Officer and Global Head of Clearing. "Vijay's deep expertise in both derivatives and securities markets will be invaluable as we continue to deliver leading risk management services to our

    4/24/25 4:00:00 AM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    $CME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CME Group Inc. (Amendment)

    SC 13G/A - CME GROUP INC. (0001156375) (Subject)

    2/13/24 5:02:29 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G/A filed by CME Group Inc. (Amendment)

    SC 13G/A - CME GROUP INC. (0001156375) (Subject)

    2/13/23 2:49:27 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G/A filed by CME Group Inc. (Amendment)

    SC 13G/A - CME GROUP INC. (0001156375) (Subject)

    2/11/22 3:04:00 PM ET
    $CME
    Investment Bankers/Brokers/Service
    Finance